Day One Biopharmaceuticals

Yahoo Finance • last month

The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in t... Full story

Yahoo Finance • last month

Oracle, Nike upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded Oracle (ORCL) to Over... Full story

Yahoo Finance • last month

Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

Quick Read After a strong Monday, the stock market took a breather yesterday as investors continued to reset in anticipation of a changing investment landscape. The potential for a quick conclusion to the Iran war is keeping the selling p... Full story

Yahoo Finance • last month

Halper Sadeh LLC is Investigating Whether DAWN, KORE, CECO are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • last month

Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Rivian (RIVN) to Buy f... Full story

Yahoo Finance • last month

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s,Qualcomm, Rivian, Strategy and More

Quick Read A stunning reversal in oil prices provided some momentum for stocks, as all major indices closed higher on Monday. West Texas Intermediate and Brent Crude both ended Monday lower after surging higher overnight. The stock market... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: Bayer, Hims & Hers and Select Medical in focus

Wall Street's major averages ended lower on Friday after nonfarm payrolls unexpectedly contracted in February and oil prices continued to rise. The benchmark S&P 500 closed -1.3%, while the Nasdaq Composite finished -1.6%, and the Dow end... Full story

Yahoo Finance • last month

US Equity Indexes Fall Amid Jobs Data Surprise, Rising Oil Prices

US equity indexes fell on Friday amid weaker-than-expected February jobs data and higher inflation f PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index and the State Str PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Day One Biopharmaceuticals reports Q4 results

* Day One Biopharmaceuticals press release [https://seekingalpha.com/pr/20411977-day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026] (DAWN [https://seekingalpha.com/symbol/DAWN]): Q4 Revenue of $52.8M... Full story

Yahoo Finance • 4 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)

BALA CYNWYD, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 5 months ago

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of al... Full story

Yahoo Finance • 5 months ago

Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more

Here's a list of key deals reported across sectors this week: Merck (MRK [https://seekingalpha.com/symbol/MRK]) to acquire [https://seekingalpha.com/pr/20307875-merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-includ... Full story

Yahoo Finance • 5 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)

BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 5 months ago

Day One to buy Mersana Therapeutics for $25/share upfront

[Antibody drug conjugated with cytotoxic payload.] Love Employee/iStock via Getty Images Day One Biopharmaceuticals (DAWN [https://seekingalpha.com/symbol/DAWN]) has signed a definitive merger agreement to acquire clinical-stage biopharma... Full story

Yahoo Finance • 5 months ago

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a can... Full story

Yahoo Finance • 5 months ago

Day One raises 2025 revenue guidance to $145M–$150M as OJEMDA sees sustained double-digit growth

Earnings Call Insights: Day One Biopharmaceuticals (DAWN) Q3 2025 MANAGEMENT VIEW * CEO Jeremy Bender highlighted Q3 as "an outstanding quarter for Day One," reporting "accelerated growth across every key dimension of OJEMDA's performa... Full story

Yahoo Finance • 6 months ago

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages... Full story

Yahoo Finance • 8 months ago

Day one Biopharma general counsel sells $29k in shares

Adam Dubow, General Counsel & Secretary of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), sold 4,365 shares of common stock on August 18, 2025, at a weighted average price of $6.7671, for a total value of $29,538. The prices for these sha... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses

Day One Biopharmaceuticals (NASDAQ:DAWN) reported a robust financial performance for the second quarter of 2025, driven by strong revenue growth and strategic expansions. The company’s stock experienced a 2.15% increase in aftermarket trad... Full story